|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||||||||
| Current assets: | |||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||
| Inventories | |||||||||||||||||||
| Deferred costs | |||||||||||||||||||
| Prepaid expenses and other current assets | |||||||||||||||||||
| Total current assets | |||||||||||||||||||
| Non-current assets: | |||||||||||||||||||
| Property, plant and equipment, net | |||||||||||||||||||
| Operating lease right-of-use assets, net | |||||||||||||||||||
| Deferred costs | |||||||||||||||||||
| Other assets | |||||||||||||||||||
| Total assets | |||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||||||||||
| Current liabilities: | |||||||||||||||||||
| Accounts payable | |||||||||||||||||||
| Accrued and other current liabilities | |||||||||||||||||||
| Deferred grant | |||||||||||||||||||
| Deferred revenue | |||||||||||||||||||
| Operating lease liabilities | |||||||||||||||||||
| Total current liabilities | |||||||||||||||||||
| Non-current liabilities: | |||||||||||||||||||
| Deferred revenue | |||||||||||||||||||
| Operating lease liabilities | |||||||||||||||||||
| Deferred grant | |||||||||||||||||||
| Total liabilities | |||||||||||||||||||
| Stockholders’ equity: | |||||||||||||||||||
| Preferred stock; $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding | |||||||||||||||||||
| Common stock; $0.0001 par value; 950,000,000 shares authorized; 146,634,469 and 134,536,592 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | |||||||||||||||||||
| Additional paid-in capital | |||||||||||||||||||
| Accumulated other comprehensive income | |||||||||||||||||||
| Accumulated deficit | |||||||||||||||||||
| Total stockholders’ equity | |||||||||||||||||||
| Total liabilities and stockholders’ equity | |||||||||||||||||||
Loading...